TITLE:
Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in Episodic Migraine Prevention: A Multicentric Observational Study
AUTHORS:
Federico Mainardi, Paola Merlo, Ferdinando Maggioni, Giorgio Zanchin, Giorgio Dalla Volta
KEYWORDS:
Migraine without Aura, Kynurenine Pathway, Tanacetum parthenium
JOURNAL NAME:
Open Access Library Journal,
Vol.5 No.8,
August
6,
2018
ABSTRACT: Objective: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop) in the prophylactic treatment of episodic migraine without aura (MO). Methods: Eighty patients suffering from MO for at least 6 months with a monthly frequency of 3 to 8 attacks and 4 to12 headache days, were enrolled in this open study and treated with Aurastop twice daily per os for 3 months. The reduction of headache days per month was assessed as the primary end-point, while the secondary end-points were: 1) reduction of the number of MO attacks; 2) reduction of intensity of the pain; 3) reduction of acute treatment drug intake; 4) subjective change of pain intensity. Results: All the parameters significantly improved at the end of the observational period of treatment with Aurastop. In more detail: a significant reduction of the number of headache days (from 9.1 ± 2.0 before treatment to 3.2 ± 1.8 post treatment, p